缺氧作为肝细胞癌经动脉化疗栓塞联合治疗的靶点
Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma.
作者信息
Wang Zizhuo, Li Qing, Liang Bin
机构信息
Hubei Key Laboratory of Molecular Imaging, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan 430022, China.
Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
出版信息
Pharmaceuticals (Basel). 2024 Aug 11;17(8):1057. doi: 10.3390/ph17081057.
Hypoxia is a hallmark of solid tumors, including hepatocellular carcinoma (HCC). Hypoxia has proven to be involved in multiple tumor biological processes and associated with malignant progression and resistance to therapy. Transarterial chemoembolization (TACE) is a well-established locoregional therapy for patients with unresectable HCC. However, TACE-induced hypoxia regulates tumor angiogenesis, energy metabolism, epithelial-mesenchymal transition (EMT), and immune processes through hypoxia-inducible factor 1 (HIF-1), which may have adverse effects on the therapeutic efficacy of TACE. Hypoxia has emerged as a promising target for combination with TACE in the treatment of HCC. This review summarizes the impact of hypoxia on HCC tumor biology and the adverse effects of TACE-induced hypoxia on its therapeutic efficacy, highlighting the therapeutic potential of hypoxia-targeted therapy in combination with TACE for HCC.
缺氧是包括肝细胞癌（HCC）在内的实体瘤的一个标志。缺氧已被证明参与多种肿瘤生物学过程，并与恶性进展和治疗耐药性相关。经动脉化疗栓塞术（TACE）是一种成熟的针对不可切除HCC患者的局部区域治疗方法。然而，TACE诱导的缺氧通过缺氧诱导因子1（HIF-1）调节肿瘤血管生成、能量代谢、上皮-间质转化（EMT）和免疫过程，这可能对TACE的治疗效果产生不利影响。缺氧已成为与TACE联合治疗HCC的一个有前景的靶点。本文综述了缺氧对HCC肿瘤生物学的影响以及TACE诱导的缺氧对其治疗效果的不利影响，强调了缺氧靶向治疗与TACE联合治疗HCC的治疗潜力。
Zotero 插件